ARMC5 Alterations in Patients With Sporadic Neuroendocrine Tumors and Multiple Endocrine Neoplasia Type 1 (MEN1)
Open Access
- 8 September 2020
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (12) , e4531-e4542
Abstract
Context Adrenal lesions are frequent among patients with sporadic neuroendocrine tumors (spNETs) or multiple endocrine neoplasia type 1 (MEN1). Armadillo repeat-containing 5 (ARMC5)-inactivating variants cause adrenal tumors and possibly other neoplasms. Objective The objective of this work is to investigate a large cohort spNETs or MEN1 patients for changes in the ARMC5 gene. Patients and Methods A total of 111 patients, 94 with spNET and 17 with MEN1, were screened for ARMC5 germline alterations. Thirty-six tumors (18 spNETs and 18 MEN1 related) were collected from 20 patients. Blood and tumor DNA samples were genotyped using Sanger sequencing and microsatellite markers for chromosomes. ARMC5 and MEN1 expression were assessed by immunohistochemistry. Results In 76 of 111 (68.4%) patients, we identified 16 different ARMC5 germline variants, 2 predicted as damaging. There were no differences in the prevalence of ARMC5 variants depending on the presence of MEN1-related adrenal lesions. Loss of heterozygosity (LOH) at chromosome 16p and ARMC5 germline variants were present together in 23 or 34 (67.6%) tumors; in 7 of 23 (30.4%) their presence led to biallelic inactivation of the ARMC5 gene. The latter was more prevalent in MEN1-related tumors than in spNETs (88.9% vs 38.9%; P = .005). LOH at the chromosome 16p (ARMC5) and 11q (MEN1) loci coexisted in 16/18 MEN1-related tumors, which also expressed lower ARMC5 (P = .02) and MEN1 (P = .01) proteins compared to peritumorous tissues. Conclusion Germline ARMC5 variants are common among spNET and MEN1 patients. ARMC5 haploinsufficiency or biallelic inactivation in spNETs and MEN1-related tumors suggests that ARMC5 may have a role in modifying the phenotype of patients with spNETs and/or MEN1 beyond its known role in macronodular adrenocortical hyperplasia.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (III41009)
- National Institutes of Health (Z01-HD008920-01)
- Ministry of Science of Republic of Serbia (III41009, 75033)
This publication has 22 references indexed in Scilit:
- ARMC5Mutations Are a Frequent Cause of Primary Macronodular Adrenal HyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 2014
- Macronodular Adrenal Hyperplasia due to Mutations in an Armadillo Repeat Containing 5 (ARMC5) Gene: A Clinical and Genetic InvestigationThe Journal of Clinical Endocrinology & Metabolism, 2014
- ARMC5Mutations in Macronodular Adrenal Hyperplasia with Cushing's SyndromeNew England Journal of Medicine, 2013
- MEN1 Is a Melanoma Tumor Suppressor That Preserves Genomic Integrity by Stimulating Transcription of Genes That Promote Homologous Recombination-Directed DNA RepairMolecular and Cellular Biology, 2013
- The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (GEP‐NET)Clinical Endocrinology, 2012
- Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'étude des Tumeurs Endocrines databaseEuropean Journal of Endocrinology, 2012
- Multiple Allelic Deletions and Intratumoral Genetic Heterogeneity in MEN1 Pancreatic Tumors1The Journal of Clinical Endocrinology & Metabolism, 2001
- Mechanisms underlying losses of heterozygosity in human colorectal cancersProceedings of the National Academy of Sciences, 2001
- Increased Expression of the Vascular Endothelial Growth Factor Is a Pejorative Prognosis Marker in Papillary Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2001
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971